The US FDA has approved Restylane Contour for the correction of temple hollowing, giving injectors an on-label option in one of the last facial zones still commonly treated off-label with hyaluronic acid fillers.

Restylane Contour, part of Galderma's Restylane portfolio, is now cleared specifically for temple volumization — a region where volume loss is often among the earliest and most visible signs of facial aging, and where practitioners have historically reached for products approved for other indications.

Why does the temple indication matter for clinics?

Temple hollowing has sat in a regulatory gap. While cheeks, lips, nasolabial folds and chin have dedicated approved indications, temple treatment has largely depended on physician discretion and off-label use. An explicit FDA indication changes several things at once:

• Treatment menus. Practices can now list temple correction as an on-label Restylane Contour service, which matters for marketing claims, consent documentation and insurer conversations.
• Training and protocols. Suppliers typically roll out indication-specific injection training when approvals land, giving clinics a standardized anatomical approach to a zone with significant vascular considerations.
• Patient communication. On-label status simplifies the informed-consent discussion for a treatment patients increasingly request as part of full-face harmonization.

For aesthetic practices, temples are also a growing entry point into global facial assessment. Patients who once asked only about nasolabial folds increasingly expect practitioners to evaluate the upper third of the face, and hollowed temples can exaggerate brow descent and lateral brow heaviness. A cleared product gives clinics a defined tool for that conversation.

What does this mean for procurement?

Buyers for medical spas and dermatology groups should expect Restylane Contour to move from a niche, off-label pick to a core stocking item for facial volumization protocols. The approval also strengthens Galderma's competitive position in the US filler market, where rival portfolios compete heavily on breadth of FDA indications rather than on rheology alone.

Formulators and brand teams watching the aesthetic-injection space should note the signal: regulators are willing to grant zone-specific indications for established hyaluronic acid products when supporting data exists, a precedent that may encourage other suppliers to pursue temple, jawline or forehead filings of their own.

What comes next?

Watch for Galderma's launch timing, pricing and any indication-specific training programs in the coming months, along with competitor filings that could follow the same regulatory pathway. The next data points to track are the full prescribing information — including recommended injection technique and volumes — and whether payers and med-spa chains begin standardizing temple correction in their treatment protocols on the strength of the new label.